The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NCI 9922: Phase 2 study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).
 
Stergios J. Moschos
Consulting or Advisory Role - Castle Biosciences; Merck Sharp & Dohme
Research Funding - Amgen; Merck Sharp & Dohme; Pharmacyclics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Zeynep Eroglu
No Relationships to Disclose
 
Elizabeth Mary Gaughan
Research Funding - Bristol-Myers Squibb; Celldex; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Novartis
 
Theresa Michelle Medina
Research Funding - Checkmate Pharmaceuticals; Genentech; Immunocore
Travel, Accommodations, Expenses - Amgen; Checkmate Pharmaceuticals; Genentech; Merck Sharp & Dohme
 
Peng Wang
No Relationships to Disclose
 
Elizabeth Claire Dees
No Relationships to Disclose
 
Leanne Cartee
No Relationships to Disclose
 
Christy Arrowood
No Relationships to Disclose
 
Craig Carson
No Relationships to Disclose
 
Nancy E Thomas
Patents, Royalties, Other Intellectual Property - UNC Chapel Hill
 
David W. Ollila
No Relationships to Disclose
 
Nana Nikolaishvilli-Feinberg
No Relationships to Disclose
 
S. Percy Ivy
No Relationships to Disclose
 
Pamela Jo Harris
No Relationships to Disclose
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)